Skip directly to search
Skip directly to A to Z list
Skip directly to navigation
Skip directly to page options
Skip directly to site content
Start of Search Controls
Search Form Controls
Search The CDC
submit
CDC A-Z Index
MENU
CDC A-Z
SEARCH
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Search Form Controls
Search The CDC
submit
CDC A-Z Index
Public Health Genomics and Precision Health Knowledge Base (v9.0)
PHGKB
About
Public Health Genomics Branch
PHGKB Weekly Horizon Scan
Genomics Precision Health Scan
Advanced Molecular Detection Clips
Non-Genomics Precision Health Scan
CDC-authored Publications Scan
Specialized PHGKB
Cancer PHGKB
Diabetes PHGKB
Economic Evaluation PHGKB
Environmental Health PHGKB
Family Health History PHGKB
Health Equity PHGKB
HLBS-PopOmics
Infectious Diseases PHGKB
Implementation Science PHGKB
Neurological Disorders PHGKB
Pharmacogenomics PHGKB
Primary Immune Deficiency Diseases PHGKB
Rare Diseases PHGKB
Reproductive and Child Health PHGKB
All Databases
COVID-19 GPH (47370)
CDC/NIH Web Information Database (32181)
CDC-Authored Genomics and Precision Health Publications Database (5878)
Precision Health Database (63675)
Tier-Classified Guidelines Database (534)
Pathogen Advanced Molecular Detection Database (26775)
All of Us Reports and Publications Database (676)
Human Genome Epidemiology
Human Genome Epidemiology Literature Finder (226516)
Epigenetic Epidemiology Publications Database (22780)
Release Note
Contact Us
Precision Health Database
Precision Health Database|Search|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Pharmacogenomics
Last data update: Apr 25, 2024
. (Total: 63675 Documents since 2012)
All
Cancer
Diabetes
Economic
Equity
Environmental
FHH
HLBS
ID
Implementation
ND
PGx
PI
Rare
RCH
dataset
All
GPH
Non-GPH
Filtered By
:
Select to fine-tune your search
Disease
Gene
Product Type
Category
Year
Previous
Records 1 - 30 (of 42 Records)
Next
Query Trace:
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Chun-Ta Huang et al. BMC cancer 2023 23(1) 234
Similar articles in PubMed
A risk stratification and prognostic prediction model for lung adenocarcinoma based on aging-related lncRNA.
Chen HuiWei et al. Scientific reports 2023 13(1) 460
Similar articles in PubMed
Integrated spatial analysis of gene mutation and gene expression for understanding tumor diversity in formalin-fixed paraffin-embedded lung adenocarcinoma.
Yamazaki Miki et al. Frontiers in oncology 2022 12936190
Similar articles in PubMed
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia David et al. Lung cancer (Amsterdam, Netherlands) 2022 174133-140
Similar articles in PubMed
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Samadder N Jewel et al. Gut 2022
Similar articles in PubMed
A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors.
Han Ji Min et al. Frontiers in oncology 2022 12790343
Similar articles in PubMed
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC.
Wang Xiao-Shan et al. Journal of the National Cancer Institute 2022
Similar articles in PubMed
Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.
Bonneville-Levard Alice et al. Medical oncology (Northwood, London, England) 2021 39(1) 4
Similar articles in PubMed
Updates in chemoprevention research for hereditary gastrointestinal and polyposis syndromes.
Hall Michael J et al. Current treatment options in gastroenterology 2021 19(1) 30-46
Similar articles in PubMed
Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi Eric K et al. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019 Jan 39e187-e197
Similar articles in PubMed
Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies.
Di Nardo Lucia et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2019 Nov
Similar articles in PubMed
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Arrieta Oscar, et al. JAMA oncology 2019 9 0. e192553
Similar articles in PubMed
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour Kathryn C, et al. JAMA 2019 0 0. (8) 764-774
Similar articles in PubMed
Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (L37810)
The U.S. Centers for Medicare & Medicaid Services
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors.
Elder J Bradley et al. Neurosurgery 2019 Mar 84(3) E201-E203
Similar articles in PubMed
[EGFR-TKI ADR Management Chinese Expert Consensus].
et al. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2019 Feb 22(2) 57-81
Similar articles in PubMed
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Socinski Mark A et al. Chest 2013 May 143(5 Suppl) e341S-e368S
Similar articles in PubMed
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.
Holleman Marscha S et al. OncoTargets and therapy 2019 121413-1421
Similar articles in PubMed
Disparities and Trends in Rates of Genetic Testing and Erlotinib Treatment Among Metastatic Non-Small Cell Lung Cancer Patients.
Palazzo Lauren L et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019 Feb
Similar articles in PubMed
Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.
Faruque Fahim et al. Journal of managed care & specialty pharmacy 2019 Feb 25(2) 260-271
Similar articles in PubMed
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-Positive Non-Small Cell Lung Cancer in China.
Cai Hongfu et al. Clinical therapeutics 2019 Jan
Similar articles in PubMed
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
Aguilar Kathleen M et al. Advances in therapy 2018 Oct
Similar articles in PubMed
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Graham Jonathan et al. Journal of managed care & specialty pharmacy 2018 Jun 24(6) 544-553
Similar articles in PubMed
Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration
SM Boca et al, JCO Precision Oncology, September 2018
Liquid Biopsy 'Weather Forecast' Can Predict When Tumors Will Return
V Forster, Forbes, August 30, 2018
Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer.
Alsharedi M et al. Drugs of today (Barcelona, Spain : 1998) 2018 Jun 54(6) 369-379
Similar articles in PubMed
Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
Kimura M et al. Molecular and clinical oncology 2018 Aug 9(2) 201-206
Similar articles in PubMed
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Aguiar Pedro N et al. JAMA oncology 2018 May
Similar articles in PubMed
Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer
Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.
Masago Katsuhiro et al. Pathology international 2018 Jan
Similar articles in PubMed
File Formats Help:
How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?
Adobe PDF file
Microsoft PowerPoint file
Microsoft Word file
Microsoft Excel file
Audio/Video file
Apple Quicktime file
RealPlayer file
Text file
Zip Archive file
SAS file
ePub file
Page last reviewed:
Feb 1, 2024
Page last updated:
Apr 25, 2024
Content source:
Public Health Genomics Branch in the Division of Blood Disorders and Public Health Genomics
,
National Center on Birth Defects and Developmental Disabilities
TOP